Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Serina Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Serina Therapeutics, Inc.

SER

Serina Therapeutics, Inc.

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary polymer-based drug delivery technologies, primarily its POZ platform, to improve the efficacy and safety of therapeutics. The company focuses on CNS disorders, notably Parkinson’s disease, with drug candidates designed for continuous delivery of dopamine agonists via subcutaneous injection. Serina’s platform enables enhanced drug loading, controlled release, and reduced immunogenicity, targeting pharmaceutical developers and patients through internal development and partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Serina Therapeutics, Inc.

1
1
Serina Therapeutics, Inc. Serina Therapeutics Reports $6.9 Million Net Loss in Q1 2026, Cash Reserves Increase to $24.5 Million

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Serina Therapeutics, Inc. Serina Therapeutics Reports $19.2 Million Net Loss and Increased R&D Expenses for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Serina Therapeutics, Inc. Serina Therapeutics Reports No Revenue and Significant Losses in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Serina Therapeutics, Inc. Serina Therapeutics Reports Revenue Growth but Incurred $6.5 Million Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Serina Therapeutics, Inc. Serina Therapeutics Reports $4.8 Million Net Loss, Focuses on SER-252 Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Serina Therapeutics, Inc. Serina Therapeutics Reports Significant Revenue Decline and Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Serina Therapeutics, Inc. Serina Therapeutics Reports Mixed Financial Results, Raises Concerns Over Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments